Asunto(s)
Disnea/diagnóstico por imagen , Disnea/terapia , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/radioterapia , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/radioterapia , Radioterapia/métodos , Anciano , Femenino , Humanos , Pulmón/patología , Pulmón/fisiología , Oxígeno/metabolismo , Fenotipo , Cintigrafía , Pruebas de Función Respiratoria , Resultado del TratamientoRESUMEN
We previously reported a 50% (95% CI = 33-76%) 5 year event-free survival (EFS) rate for 23 patients with Hodgkin's disease (HD) who received salvage therapy with single agent high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT). Predictors of poor outcome included bulky disease and initial remission <1 year. Since 1995, similar poor prognosis patients have been treated with double high-dose therapy consisting of dose-intensive cyclophosphamide 5.25 g/m2, etoposide 1.05 g/m2, cisplatin 105 mg/m2 (DICEP) for tumor cytoreduction and stem cell mobilization followed by HDM/ASCT. The purpose of the present study is to determine if the use of DICEP is associated with improved event-free (EFS) and overall survival (OAS) for patients treated with HDM/ASCT. From February 1981 to June 1999, 46 consecutive patients received HDM/ASCT for relapsed (n = 35) or refractory (n = 11) HD. DICEP re-induction and blood stem cell mobilization was used for 21 patients. Factors considered for univariate and multivariate analyses included age at transplant, number of failed chemotherapy regimens, prior radiotherapy, length of initial remission, relapsed or refractory disease status, extranodal relapse, B symptoms at relapse, bulk, post-ASCT radiotherapy, and DICEP re-induction therapy. Cox proportional hazards models were constructed for both event and death. DICEP and HDM were well tolerated with no early treatment-related mortality or toxicity requiring life-sustaining measures. For all 46 patients, the projected 5 year EFS was 52% (95% CI = 38-72%) and OAS was 57% (95% CI = 40-82). Factors independently associated with relapse in multivariate analysis included bulk >5 cm (RR = 6.38, P = 0.002), prior radiotherapy (RR = 3.59, P = 0.027), and not using DICEP (RR = 5.29, P = 0.005). Factors independently associated with death included bulk >5 cm (RR = 5.13, P = 0.009), > or =3 prior chemotherapy regimens (RR = 4.72, P = 0.019), and not using DICEP (RR = 7.49, P = 0.015). This study demonstrates that DICEP re-induction prior to HDM/ASCT is feasible. The preliminary data are sufficiently encouraging to warrant a multicenter phase II or a phase III trial evaluating DICEP followed by HDM/ASCT as salvage therapy for HD.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Cisplatino/administración & dosificación , Ciclofosfamida/administración & dosificación , Etopósido/administración & dosificación , Trasplante de Células Madre Hematopoyéticas/métodos , Enfermedad de Hodgkin/tratamiento farmacológico , Melfalán/administración & dosificación , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Eliminación de Componentes Sanguíneos/métodos , Cisplatino/toxicidad , Terapia Combinada , Ciclofosfamida/toxicidad , Supervivencia sin Enfermedad , Etopósido/toxicidad , Estudios de Seguimiento , Trasplante de Células Madre Hematopoyéticas/normas , Humanos , Persona de Mediana Edad , Análisis Multivariante , Modelos de Riesgos Proporcionales , Factores de Riesgo , Tasa de Supervivencia , Trasplante Autólogo/métodos , Trasplante Autólogo/normas , Resultado del TratamientoRESUMEN
BACKGROUND: The incidence of primary CNS lymphoma (PCNSL) is believed to be increasing in immunocompetent patients but this may not be universally true. The objective of this study was to determine in a population if the incidence of PCNSL is increasing, if the histologic subtypes are changing, and to describe the clinicopathologic and outcome characteristics of PCNSL. PATIENTS AND METHODS: We identified all Alberta residents with a histologic diagnosis of PCNSL from 1 January 1975 to 31 December 1996 using the Alberta Cancer Registry. Annual age-standardized incidence rates (ASIR), clinicopathologic and outcome characteristics were determined. RESULTS: There were 50 immunocompetent PCNSL patients; the median age was 64 and 30 were male. Their median survival was 10.15 months. Histology was available for review in 37 (74%) patients: 19 (51%) were diffuse large cell, 16 (43%) were immunoblastic and 2 (5%) were unclassifiable malignant lymphomas. The ASIR ranged from 0.178-1.631/10(6) and no change in ASIR was found (test for trend, P = 0.26) for gender or age. The ASIR of malignant gliomas did not change either but increased for all other non-Hodgkin's lymphoma (94.95-138.7610(6); test for trend, P = 0.0001) The number of brain biopsies increased from 1979-1985 (test for trend, P < 0.0001) but remained stable from 1986-1996 (test for trend, P = 0.99). CONCLUSIONS: Unlike several other populations, PCNSL is not becoming significantly more common in Alberta. If this difference is real (i.e., not due to differences in cancer registry coding practices etc.) comparisons between Albertans and other populations in whom the incidence is rising may provide clues regarding the etiology of PCNSL.
Asunto(s)
Neoplasias Encefálicas/epidemiología , Linfoma no Hodgkin/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Alberta/epidemiología , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/terapia , Niño , Terapia Combinada , Femenino , Humanos , Incidencia , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , Pronóstico , Sistema de Registros , Factores de Riesgo , Distribución por Sexo , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Few data are available on the cost, safety, and long-term efficacy of single-agent high-dose melphalan (HDM) followed by autologous bone marrow (ABMT) or blood stem cell (ABSCT) transplantation in the salvage therapy of Hodgkin's disease (HD). PATIENTS AND METHODS: From February 1981 to September 1996, 23 patients with relapsed (n = 15) or refractory (n = 8) HD received salvage therapy with HDM 140-200 mg/m2 followed by non-cryopreserved ABMT (n = 18) or cryopreserved ABSCT (n = 5). The cost of HDM/ABSCT in 1996, from initial consultation until transfer back to referring physician, was determined and compared to the estimate costs of two multi-agent regimens commonly used for HD. RESULTS: HDM was well tolerated with no early transplant-related mortality. The five-year overall and progression-free survival rates were 52% and 50%, respectively. The average total cost in Canadian funds of HDM/ABSCT in 1996 was $34,400/patient. This cost was estimated to be $4,700-6,800 cheaper per patient than the multi-agent high-dose regimens. CONCLUSION: These data suggest that HDM is safe, feasible, active, and reasonably inexpensive salvage therapy for patients with relapsed/refractory HD.
Asunto(s)
Antineoplásicos Alquilantes/economía , Antineoplásicos Alquilantes/uso terapéutico , Enfermedad de Hodgkin/tratamiento farmacológico , Melfalán/economía , Melfalán/uso terapéutico , Adolescente , Adulto , Antineoplásicos Alquilantes/efectos adversos , Trasplante de Médula Ósea , Terapia Combinada , Femenino , Trasplante de Células Madre Hematopoyéticas , Humanos , Masculino , Melfalán/efectos adversos , Persona de Mediana EdadRESUMEN
The use of a digital camera to simulate irregularly shaped electron treatment fields was investigated. The simulation of electron treatment fields, drawn on patient's skin or shell, is required to fabricate cerrobend inserts for defining the beam apertures. The use of the digital camera made the procedure very easy and time efficient, which was essential for patient comfort as well. The mathematical formulism and accessories required to use the camera for simulating the electron treatment fields are described in detail.
Asunto(s)
Simulación por Computador , Procesamiento de Imagen Asistido por Computador , Dosificación Radioterapéutica , Radioterapia Asistida por Computador , Electrones/uso terapéutico , Humanos , Aceleradores de Partículas , Fantasmas de Imagen , Fotograbar/instrumentación , Radioterapia/instrumentación , Planificación de la Radioterapia Asistida por Computador , Piel/efectos de la radiaciónRESUMEN
Direct involvement of the brain by chronic lymphocytic leukemia (CLL) is extremely rare. This is the second documented case. A 63 year-old-man presented with motor deficits. Conventional radiographic imaging showed no abnormalities but an MRI scan of the head showed a high signal intensity lesion in the left cerebellum. Biopsy of this area showed a perivascular infiltrate of small B lymphocytes consistent with CLL involvement. The patient was treated with radiotherapy and had some improvement in symptoms. Three years later he remains alive with some neurologic deficit. This case confirms that CLL can be complicated by direct brain involvement.